Patheon Announces Annual and Special Shareholder Meeting Web Cast

TORONTO, March 13, 2012 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it will host a conference call and Web cast allowing interested persons to listen to its Annual and Special Meeting of Shareholders (the "Annual Meeting") to be held on Thursday, March 22, 2012, beginning at 10:30 a.m. (EDT).  The Annual Meeting will be held at The Fairmont Royal York Hotel in Toronto, Ontario, Canada.  Patheon's 2011 Annual Report and its Proxy Statement and Information Circular for the Annual Meeting can be viewed at www.envisionreports.com/Patheon2012.

Interested parties are invited to listen to the annual meeting, via telephone, toll free at [phone] (U.S., including Puerto Rico) and [phone] (Canada and International).  To view the slides accompanying the annual meeting presentation click here.  The link to the Web cast will also be posted on the investor relations section of Patheon's Web site prior to the call.  Persons wishing to listen to the Annual Meeting are encouraged to dial in five to fifteen minutes in advance to avoid delays.  A live audio will also be available via the web at http://ir.patheon.com/events.cfm. (Please note that either Windows Media Player or RealPlayer are required).

A telephone replay of the Annual Meeting will be available between March 22, 2012 and April 5, 2012 by dialing 1-855-859-2056 (toll free) or 1-403-451-9481, and by entering identification number 59993373, followed by the number key.  The Web cast will also be archived at http://ir.patheon.com/events.cfm.

About Patheon
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry.  The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies.  Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, soft gel, solid and liquid forms.

The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization.  The company's integrated development and manufacturing network of 10 manufacturing facilities, nine development centers and one clinical trial material packaging facility across North America and Europe, enables customer products to be launched with confidence anywhere in the world.

Contact:
Wendy Wilson
Investor Relations and Corporate Communications
Tel: [phone]
Email: [email protected]